Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padsevonil PK and Safety with Erythromycin in Healthy Volunteers
NCT03480243Phase 1Completed
- Sponsor
- UCB
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of padsevonil in epilepsy, sponsored by UCB. Primary endpoints: Maximum Observed Plasma Concentration at Day 26, Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours and 2 more. Started Mar 2018; status: completed.
02
Drugs
padsevonil
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03480243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480243.